You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

12 Items
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB Limited Use
    letrozole - Treatment of metastatic breast cancer in hormone receptor positive postmenopausal women
Drugs Used:
abemaciclib (Unfunded),
Jun 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
Exceptional Access Program
    Treatment of non-small cell lung cancer according to clinical criteria
Jun 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Drugs Used:
carfilzomib (Unfunded)
Jun 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Carfilzomib (Doublet Therapy) - In Combination with Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Sep 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Carfilzomib (Triplet Therapy) - In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    lenalidomide - In combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma
Oct 2019
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
Funding:
ODB - General Benefit
  • flutamide
Oct 2016
Cancer Type: Breast     
Intent: Adjuvant
Funding:
ODB Limited Use
  • letrozole - As an alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer for a maximum of five years
ODB Limited Use
  • letrozole - Treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy
May 2016
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB Limited Use
  • letrozole - Treatment of metastatic breast cancer in hormone receptor positive postmenopausal women
May 2016
Cancer Type: Gynecologic, Ovary     
Intent: Palliative
Drugs Used:
letrozole (Unfunded)
Jun 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative unresectable locally advanced breast cancer or metastatic breast cancer, according to clinical criteria
ODB Limited Use
    letrozole - Treatment of metastatic breast cancer in hormone receptor positive postmenopausal women
Jun 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of breast cancer according to clinical criteria
ODB Limited Use
    letrozole - Treatment of metastatic breast cancer in hormone receptor positive postmenopausal women
Sep 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    niLOtinib - Chronic phase Ph+ CML, with specific criteria
Exceptional Access Program
    niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria
Jun 2019